Please try another search
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. The company was founded in 2001 and is based in Dijon, France.
Name | Age | Since | Title |
---|---|---|---|
Eric Nemeth | - | 2012 | Independent Vice Chairman of the Supervisory Board |
Philippe Monnot | - | - | Chairman of Supervisory Board |
Yannick Pletan | - | 2019 | Member of Supervisory Board |
Jean-Francois Loumeau | - | 2018 | Member of Supervisory Board |
Daniel Gedeon Teper | 64 | 2023 | Member of Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review